FDA approves semaglutide (Wegovy®) for MASH: What does this mean for drug development and preclinical innovation?
As the drug development landscape evolves, the need for reliable and translational preclinical MASH models has never been greater.
Which IPF model offers the highest translational relevance in preclinical research?
The development of effective therapies for Idiopathic Pulmonary Fibrosis (IPF) relies fundamentally on selecting the appropriate in vivo preclinical mouse model. While the bleomycin model remains the cornerstone of preclinical research services, achieving maximal clinical relevance is not about finding…
How to choose the right model for atherosclerosis studies
The efficacy of an anti-atherosclerotic compound is only as good as the method used to measure it. Explore the difference between the DIO-LDLR-KO mouse model and the DIO-AAV-PCSK9 mouse model.
The role of preclinical fibrosis models in advancing kidney disease research
Explore a broad portfolio of robust and translational renal fibrosis models that are essential for evaluating the efficacy of new drug candidates.
Closing the preclinical gap: How better research models can transform women’s health
We highlight the need for better preclinical models tailored to female biology and beyond.
How GubraView™ transforms data accessibility in preclinical research
GubraView offers advanced visualization and quantification tools that allow researchers to assess and evaluate histological and imaging data more efficiently and accurately.
5 Reasons to choose Gubra as a preclinical partner
Selecting a CRO (contract research organization) is an important step in any pharmaceutical or biotechnology company’s preclinical development.